DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for neurosyphilis — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleNeurosyphilis maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for neurosyphilis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
C-X-C motif chemokine ligand 13 (CXCL13) — CXCL13 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7JNY · 1.88 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
Penicillin has been the mainstay of neurosyphilis treatment for decades, but the evidence base for optimal dosing and preparation remains thin. A 1974 review noted that there were very few clinical studies to indicate the proper dosage and preparation of penicillin for congenital syphilis, and that current recommendations made no distinction between infants with or without central nervous system disease. The authors proposed revised schedules based on pharmacologic data, explicitly in the absence of adequate clinical experience. A 1982 review of benzathine penicillin G found that few well-controlled studies existed to document its efficacy conclusively in neurosyphilis, and it cited recent case reports of treatment failures. The same review nonetheless recommended its use in selected situations.
Earlier literature emphasised the importance of early treatment. A 1944 review stated that early treatment was imperative to obtain good results and that neurosyphilis itself must be regarded as a preventable disease. A 1945 book on the management of neurosyphilis was published, but no trial data from that era are provided in these abstracts. The diagnostic problem of congenital neurosyphilis was already noted in 1974: cerebrospinal fluid serologic studies may be falsely reactive, forcing clinicians to treat infants as if they have neurosyphilis despite a lack of confirmatory laboratory data.
More recent publications do not report new treatment trials. A 2023 article proposed the CARE-NS research strategy to enhance clinical management, noting that the overall incidence of neurosyphilis remains unknown and that there is a lack of understanding of disease pathogenesis, which hampers clinical management and prevention. A 2025 review stated that neurosyphilis remains a highly morbid neurologic infection and that recent years have seen a dramatic increase in incidence across various populations, but it offered no new efficacy data for any drug. What is still missing are adequately controlled trials comparing penicillin regimens, validated diagnostic criteria that distinguish true neurosyphilis from false-positive CSF results, and prospective studies that link treatment to neurological outcomes rather than serological surrogates. Funding for such trials, clear patient stratification by stage and immune status, and standardised outcome measures are all absent.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
JAMA · 1974 · 35 citations
Penicillin Treatment for Congenital Syphilis
AbstractThe asymptomatic infant with suspected congenital neurosyphilis poses a diagnostic and therapeutic problem. Because cerebrospinal fluid serologic studies may be falsely reactive, the clinician is frequently forced to treat infants as if they have neurosyphilis despite the lack of confirmatory laboratory data. There are very few clinical studies to indicate the proper dosage and preparation of penicillin for treatment of congenital syphilis. The current recommendations for treatment make no distinction for infants with or without neurosyphilis. Revised treatment schedules for congenital syphilis with or without central nervous system disease are proposed in accordance with the available pharmacologic data and in the absence of adequate clinical experience. (<i>JAMA</i>228:855-858, 1974)
AbstractAn extensive review of recent advances in the aetiology and treatment of neurosyphilis was published in this journal by one of us, E. L. Hutton (1941). While it is mainly the later manifestations with their crippling disabilities that present themselves to the psychiatrist in the mental hospital, it is becoming increasingly obvious that early treatment is imperative to obtain good results, and that neurosyphilis itself must be regarded as a preventable disease.
Benzathine Penicillin G in the Treatment of Neurosyphilis
AbstractThe definition, pathogenesis, incidence, diagnosis, and treatment of neurosyphilis are discussed. Controlled trials of benzathine penicillin in the treatment of neurosyphilis are reviewed, as are recent case reports of benzathine penicillin failures. Although few well-controlled studies exist to document conclusively the efficacy of benzathine penicillin in the treatment of neurosyphilis, its use is recommended in selected situations.
AbstractJournal Article The Management of Neurosyphilis Get access The Management of Neurosyphilis. By Bernhard Dattner, M.D., Associate Clinical Professor of Neurology, New York University; Assistant Visiting Neuropsychiatrist, Bellevue Hospital; Attending Neurologist, Bronx Hospital; Associate Visiting Neuropsychiatrist, Welfare Hospital, New York City; Associate Neurologist, Jewish Hospital of Brooklyn. Cloth. Price, $5.50. Pp. 275, with 40 illustrations and tables. New York: Grune & Stratton, Inc., 1943. Physical Therapy, Volume 25, Issue 1, January 1945, Page 52, https://doi.org/10.1093/ptj/25.1.52b Published: 01 January 1945
Frontiers in Medicine · 2023 · 7 citations · open access
CARE-NS, a research strategy for neurosyphilis
AbstractNeurosyphilis is a major clinical manifestation of syphilis. In recent years, an increase in neurosyphilis cases has been reported in many countries. The overall incidence of neurosyphilis remains unknown, and there is a lack of understanding of the disease pathogenesis, which hampers clinical management, development of prevention strategies, and control. This article proposes the CARE-NS research strategy to enhance the clinical management of neurosyphilis, which consists of six key features: comprehensive management including multidisciplinary treatment (C), alleviating neurological impairment and sequelae (A), risk factors and clinical epidemiology (R), etiology and pathogenesis (E), new diagnostic indicators and strategies (N), and social impact and cost-effectiveness analysis (S).
AbstractNeurosyphilis remains an important and highly morbid neurologic infection. Recent years have seen a dramatic increase in the incidence of syphilis across a variety of populations, making recognition of the many neurologic complications of this infection still relevant for modern clinicians. As manifestations of neurosyphilis are famously varied, a high index of suspicion is essential, especially in the face of atypical presentations. In this review, we discuss updates to the epidemiology, range of clinical presentations, diagnosis, and management of neurosyphilis. ANN NEUROL 2025;98:1070-1076.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
